Russian Direct Investment Fund says it will supply 100 million doses of Sputnik-V COVID-19 vaccine to Dr Reddy's Laboratories for trial and distribution in India after regulatory approval
The Russian Direct Investment Fund (RDIF) on Wednesday said it will supply Dr Reddy’s Laboratories with 100 million doses of the Sputnik-V Covid-19 vaccine for trial and distribution in India. Both the trials and supply deal depend on central drug regulator's approval.
“India is amongst most severely impacted countries from COVID 19 and we believe our human adenovirus dual vector platform will provide a safe and scientifically validated option to India in the battle against covid-19. Deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India,” RDIF chief executive officer Kirill Dmitriev said in a statement.
Commenting on the tie-up, G V Prasad, co-chairman & managing director of Dr Reddy’s Laboratories said, "We will be conducting Phase-III trials in India to ensure safety and efficacy for the Indian population and to meet the requirements of the Indian regulators. Sputnik V vaccine could provide a credible option in our fight against COVID 19 in India."
Last week NITI Aayog member (health) VK Paul said the Indian government is willing to facilitate a phase 3 trial for Russia’s Sputnik V vaccine for which 2-4 Indian companies are in discussions to mass manufacture.
Developed by Gamaleya National Research Institute of Epidemiology and Microbiology on August 11, the Sputnik-V vaccine was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against Covid-19 based on the human adenoviral vectors platform.
"The platform of human adenoviral vectors, which is the core of the Russian vaccine, has been tested in more than 250 clinical studies over decades, and it has been found safe with no potential negative long-term consequences," Dmitriev claimed.